{{header
 | author     = Joseph R. Pitts
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2014
 | month      = 03
 | day        = 26
 | notes      = ''{{USBill|113|H.R.|4299}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 2
 | title      = Improving Regulatory Transparency for New Medical Therapies Act ( H.R. 4299; 113th Congress)
 | bill       = 4299
 | billtype   = hr
 | purpose    = To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.
 | wikipedia  =
}}
      Union Calendar No. 451 
{{Center|113th CONGRESS}}

 
{{Center|2d Session}}

 
{{Center|H. R. 4299}}

 <nowiki>[Report No. 113–565, Parts I and II]</nowiki> 
{{Center|IN THE HOUSE OF REPRESENTATIVES}}

  
{{Center|March 26, 2014}}

 
{{Center| 
[[w:Joseph R. Pitts|Mr. Pitts]](for himself and
[[w:Frank Pallone|Mr. Pallone]]) introduced the following bill; which was referred to the [[w:United States House Committee on Energy and Commerce|Committee on Energy and Commerce]], and in addition to the [[w:United States House Committee on the Judiciary|Committee on the Judiciary]], for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned}}

   
{{Center|July 29, 2014}}

 
{{Center|Reported from the [[w:United States House Committee on Energy and Commerce|Committee on Energy and Commerce]] }}

   
{{Center|July 29, 2014}}

 
{{Center|Referral to the [[w:United States House Committee on the Judiciary|Committee on the Judiciary]]extended for a period ending not later than September 19, 2014}}

   
{{Center|September 19, 2014}}

 
{{Center|Additional sponsors:
[[w:Michael C. Burgess|Mr. Burgess]],
[[w:Cathy McMorris Rodgers|Mrs. McMorris Rodgers]],
[[w:Marsha Blackburn|Mrs. Blackburn]],
[[w:Phil Gingrey|Mr. Gingrey of Georgia]],
[[w:Morgan Griffith|Mr. Griffith of Virginia]],
[[w:Gene Green|Mr. Gene Green of Texas]],
[[w:Bob Latta|Mr. Latta]],
[[w:Eliot Engel|Mr. Engel]],
[[w:Carol Shea-Porter|Ms. Shea-Porter]],
[[w:G. K. Butterfield|Mr. Butterfield]],
[[w:Paul Tonko|Mr. Tonko]],
[[w:Bill Johnson (Ohio politician)|Mr. Johnson of Ohio]],
[[w:Gregg Harper|Mr. Harper]], and
[[w:Doug Collins (politician)|Mr. Collins of Georgia]] }}

   
{{Center|  }}

   
{{Center|September 19, 2014}}

 
{{Center|Reported from the [[w:United States House Committee on the Judiciary|Committee on the Judiciary]]with an amendment}}

 Strike out all after the enacting clause and insert the part printed in italic For text of introduced bill, see copy of bill as introduced on March 26, 2014  
{{Center|A BILL}}

 To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.    

=Section 1. Short title=

This Act may be cited as the“   Improving Regulatory Transparency for New Medical Therapies Act   ”. 

=Sec. 2. Scheduling of substances included in new FDA-approved drugs=

   Section 201(a) of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/811 21 U.S.C. 811(a)] )is amended by adding at the end the following:“Any such proceedings initiated at the request of the [[w:Department of Health and Human Services|Secretary]]under this subsection to control a drug or other substance not previously scheduled, where the [[w:Department of Health and Human Services|Secretary]]has recommended the drug or other substance be placed in schedule II, III, IV, or V, shall be commenced not later than 120 days after receipt of written recommendations from the [[w:Department of Health and Human Services|Secretary]]. The final rule shall be issued not later than 60 days after the date on which both the public comment period has closed and the drug or other substance is the subject of an approved new drug application under section 505 of the Federal Food, Drug, and Cosmetic Act , unless a hearing on the proposed rule is granted by the [[w:United States Department of Justice|Attorney General]].”. 

=Sec. 3. Enhancing new drug development=

   Section 303 of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/823 21 U.S.C. 823] )is amended by adding at the end the following:

<blockquote> 
:(i) 
::(1) For the purposes of registration to manufacture a controlled substance under subsection (d) of this section for use only in a clinical trial, the [[w:United States Department of Justice|Attorney General]]shall register an applicant or serve an order to show cause upon an applicant pursuant to section 304(c) of this Act not later than 180 days after receipt of an application and all information the [[w:United States Department of Justice|Attorney General]]deems necessary to make a determination under subsection (d).
::(2) For the purposes of registration to manufacture a controlled substance under subsection (a) for use only in a clinical trial, the [[w:United States Department of Justice|Attorney General]]shall, in accordance with regulations issued by the [[w:United States Department of Justice|Attorney General]], issue a notice of application not later than 90 days after receipt of an application and all information the [[w:United States Department of Justice|Attorney General]]deems necessary to issue a notice of application. Following the close of the comment period and receipt of all information the [[w:United States Department of Justice|Attorney General]]deems necessary to make a determination under subsection (a), the [[w:United States Department of Justice|Attorney General]]shall register an applicant or serve an order to show cause upon an applicant pursuant to section 304(c) of this Act within 180 days, unless a hearing on the application has been granted by the [[w:United States Department of Justice|Attorney General]]pursuant to section 1008(i) of the Controlled Substances Import and Export Act . . 
</blockquote>
   
{{Center|September 19, 2014}}

 
{{Center|Reported from the [[w:United States House Committee on the Judiciary|Committee on the Judiciary]]with an amendment}}

  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
